A patient opts for a novel clinical trial and thrives with stage 4 colorectal cancer.
In May, the FDA approved atezolizumab in combination with bevacizumab for newly diagnosed patients with hepatocellular carcinoma.
Is checkpoint inhibitor-related polymyalgia rheumatica (PMR) distinct from the classic rheumatic disease, or does it represent new clinical variants with potentially different pathogenesis, clinical course and treatment responsiveness? Rheumatologist/immunologist Cassandra Calabrese, DO, discusses her research, which identified clinical features that are unusual in idiopathic PMR.
A common occurrence in the age of cancer immunotherapy, immune-related adverse events require multidisciplinary collaboration for investigation and optimal management. Drs. Cassandra and Leonard Calabrese discuss the ever-evolving field and the need for continuing education.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The goal of the tumor board is to discuss new and/or challenging cases of irAEs, review the extant literature and receive input on interprofessional management.
Checkpoint inhibitor therapy for cancer holds great potential for durable response rates, but immune-related adverse events may be its Achilles’ heel.